Su 2017.

Study characteristics
Methods	Double‐blind, randomised, parallel‐group, placebo controlled trial
Participants	Diagnosis: DSM‐IV major depressive disorder N: 71 Age: ketamine 0.5 mg/kg group M = 48.5 (SD = 11.0); ketamine 0.2 mg/kg group M = 45.0 (SD = 12.3); placebo group M = 48.6 (SD = 8.2) Sex: ketamine 0.5 mg/kg group 87.5% female; ketamine 0.2 mg/kg 73.9% female; placebo group 62.5% female Baseline depression severity: ketamine 0.5 mg/kg group HAMD‐17 score M = 23.0 (SD = 4.9); ketamine 0.2 mg/kg group HAMD‐17 score M = 23.1 (SD = 4.8); placebo group HAMD‐17 score M = 23.3 (SD = 4.1)
Interventions	Patients were randomised to receive a 40‐minute intravenous infusion ketamine (0.2 mg/kg or 0.5 mg/kg) or saline.
Outcomes	HAMD‐17 MADRS BDI Blood pressure Heart rate Digit pulse oximetry Response (≥ 50% reduction of HAMD‐17 score at any two daily HAMD measures during the period of 24 to 96 hours (days 2 to 5) after infusion.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details on randomisation procedures given
Allocation concealment (selection bias)	Unclear risk	No details on allocation concealment given
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Stated but not tested
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details about blinding of outcome assessment given
Incomplete outcome data (attrition bias) All outcomes	Low risk	Consort flow diagram with details of attrition included in figure 1 (page 2843)
Selective reporting (reporting bias)	Low risk	Trial registration available online (UMIN000016985). Outcomes all reported.
Other bias	Low risk	None identified